BIMZELX (bimekizumab) - In plaque psoriasis, psoriatic arthritis and hidradenitis suppurativa

Opinions on drugs - Posted on Jan 09 2025

Reason for request

First listing

Favourable opinion for reimbursement in the MA indications, in adults, in plaque psoriasis, psoriatic arthritis and hidradenitis suppurativa (for more information see the MA).

No clinical added value of the new forms compared to the forms already available: BIMZELX 160 mg (bimekizumab) solution for injection in pre-filled syringe (B/2) and solution for injection in pre-filled pen (B/2).

Clinical Benefit

Substantial	The Committee considers that the clinical benefit of BIMZELX 320 mg (bimekizumab) solution for injection in pre-filled syringe or pre-filled pen is low in the MA indication.
Low

Clinical Added Value

no clinical added value

The Committee considers that the clinical benefit of BIMZELX 320 mg (bimekizumab) solution for injection in pre-filled syringe or pre-filled pen is low in the MA indication.